Sun Pharmaceutical Industries Limited (SUNPHARMA) share price and analysis
SUNPHARMA last traded at ₹1,870.00 (+0.13%) on the NSE. Market cap ₹4,48,676 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 6.4/10 (Average)
- Valuation: 5.7/10
- Profitability: 6.1/10
- Growth: 3.8/10
- Financial health: 9.3/10
- Price trend: 7.0/10
Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of SUNPHARMA
- Debt / equity (0.04): Virtually debt-free, with a strong balance sheet.
- Long-term trend (+2.9% vs 200-DMA): Just above its 200-day average. Still an uptrend, but not by much.
- Momentum (RSI 14) (RSI 62): Strong bullish momentum without being overbought.
- Net profit margin (17.8%): Healthy profit margins.
- Revenue growth (YoY) (+11.9%): Solid sales growth.
- Current ratio (2.94): Plenty of short-term assets to cover short-term bills.
- 50-DMA vs 200-DMA (+0.1% gap): 50-day average is just above the 200-day. Momentum is turning up.
- Free cash flow (1.7% FCF yield): Generates healthy free cash flow.
- Analyst target (₹2,112 (+12.9%)): 33 analysts' average target implies +12.9%, moderate upside.
- Volatility (1Y) (20% annualised): Low volatility. A relatively steady stock.
- 52-week range (9% below high): In the upper half of its 52-week range.
Weaknesses of SUNPHARMA
- Profit growth (YoY) (-36.2%): Profits are falling sharply.
- 6-month performance vs Nifty 50 (-0.4% vs +7.4%): Lagging the Nifty 50.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 40.9 | In line with peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 29.8 | Profits expected to grow | below today's P/E (40.9) and near 41 |
| Price / book | 5.02 | Normal | 2–6 |
| EPS (TTM) | ₹45.70 | Profitable | above ₹0 |
| Return on equity | 13.1% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.04 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 17.8% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 23.3% | Strong | 20%+ strong, below 10% thin |
| Revenue growth | +11.9% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | -36.2% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.86% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 2.94 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹2,046.90 | 9% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹1,583.70 | Price is 18% above it | |
| 50-DMA | ₹1,818.71 | Price 2.8% above | price above it = short-term uptrend |
| 200-DMA | ₹1,817.61 | Price 2.9% above | price above it = long-term uptrend |
| 1Y return | +10.1% | Beat the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.13 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 55.6% | Owners have a big stake | 50%+ shows owner commitment |
| Institutions | 30.3% | Strong big-investor interest | 30%+ is strong |
| Analyst target | ₹2,111.94 | 12.9% upside · 33 analysts | 8%+ upside |
Questions about SUNPHARMA
What is the share price of Sun Pharmaceutical Industries Limited (SUNPHARMA) today?
SUNPHARMA last traded at ₹1,870.00 (+0.13% on the day) on the NSE. Its 52-week range is ₹1,583.70 to ₹2,046.90. Prices are delayed and come from Yahoo Finance.
Is SUNPHARMA a good stock for the long term?
StockLens rates SUNPHARMA 6.4 out of 10 (Average) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: low debt, uptrend, strong momentum. Concerns: falling profits, lagging the market.
Is SUNPHARMA share overvalued?
SUNPHARMA trades at a P/E of 40.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "In line with peers". Its price-to-book ratio is 5.02.
Is SUNPHARMA good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 2.9% above its 200-day average and 14-day RSI is 62.
Which stocks are similar to SUNPHARMA?
Similar Pharma & Healthcare stocks of comparable size include Divi's Laboratories, Torrent Pharmaceuticals, Laurus Labs, Apollo Hospitals, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Stocks similar to SUNPHARMA
- Divi's Laboratories share price
- Torrent Pharmaceuticals share price
- Laurus Labs share price
- Apollo Hospitals share price
- Zydus Lifesciences share price
- Dr. Reddy's Laboratories share price
Compare SUNPHARMA with DIVISLAB, TORNTPHARM, LAURUSLABS
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.